Clinical Trial

Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer

Study acronym: MAPPER
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an exploratory phase II interventional study that initiates standard-of-care anti-estrogen treatment preoperatively for 4-12 weeks (+/- 2 weeks).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-04-08; most recent amendment 2025-10-09.
Status change: Not Yet Recruiting → Recruiting 2024-10-03
Trial Details
NCT Number NCT06361940
Lead Sponsor Medical College of Wisconsin
Conditions Breast Cancer
Enrollment 100 participants
Start Date 2024-09-30
Primary Completion 2028-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2025-10-14